The economic evaluation of pharmacotherapies for Parkinson's disease
| Autor: | Mark Guttman, Doug Coyle, J.-F. Baladi, M. Barbeau |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Canada Cost effectiveness media_common.quotation_subject Cost-Benefit Analysis Psychological intervention Catechols Disease Drug Costs Scarcity Antiparkinson Agents Health care Nitriles medicine Humans Entacapone Psychiatry media_common Health economics business.industry Parkinson Disease Neurology Economic evaluation Neurology (clinical) Geriatrics and Gerontology business medicine.drug |
| Zdroj: | Parkinsonismrelated disorders. 9(5) |
| ISSN: | 1353-8020 |
| Popis: | As well as the significant clinical effects of Parkinson's disease (PD), the disease places a high economic burden on society. Given the scarcity of health care resources, it is becoming increasingly necessary to demonstrate that new therapies for PD provide value for money in comparison with other potential interventions. This paper outlines the basic techniques of cost-effectiveness analysis and its application to PD. These techniques are illustrated by a recent economic evaluation of entacapone for use in Canada. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect